This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutUnmet NeedCommunity-acquired PneumoniaComplicated Skin & Soft Tissue InfectionsMode of ActionVideoCommunity-acquired PneumoniaComplicated Skin & Soft Tissue InfectionsPatient ProfilesProfiles of Patients With CAPIdentify ZINFORO® Patient With CAPProfiles of Patients With cSSTIIdentify ZINFORO® Patient With cSSTIDosingRecommended Dosing ScheduleSimple DosingRenal AdjustmentEfficacyCommunity-acquired PneumoniaClinical Efficacy: Proven Clinical EfficacyClinical Efficacy: Evidence of Rapid ResponsePivotal Clinical StudiesMicrobiology: Optimising OutcomesMicrobiology: CoverageMicrobiology: Low MIC ValuesComplicated Skin & Soft Tissue InfectionsClinical Efficacy: Proven Clinical EfficacyClinical Efficacy: Evidence of Rapid ResponsePivotal Clinical StudiesMicrobiology: Optimising OutcomesMicrobiology: CoverageMicrobiology: Low MIC ValuesSafetySafetyKey safety featuresLow Incidence of Discontinuation in CAPLow Incidence of Discontinuation in cSSTIClinical & Scientific Data Clinical & Scientific Data Efficacy in the Treatment of CAPClinical Cure Rates Against Relevant PathogensClinical Cure Rates Across Patient SubgroupsDemonstrated Superiority to CeftriaxoneEarly Clinical ResponseReal-world Efficacy in Elderly PatientsConsistent Clinical Cure Rates in cSSTIClinical Cure Rates in Common Causative PathogensClinical Cure Rates in Patients With ComorbiditiesEarly Clinical EfficacyReal-life Efficacy in Clinical PracticeSupport & ResourcesSupport & ResourcesClinical updatesPrescribing InformationVideosWebinars

Real-life Efficacy in Clinical Practice

Real-world efficacy in clinical practice: An overall clinical success rate of 85% in cSSTI1,2

Header
Header Header Header
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content

Prior antibiotic use in CAPTURE1,* 

Antibiotics were administered prior to ZINFORO® treatment in 80% of patients. Clinical success rates in these subgroups were as follows:

  • Patients receiving ZINFORO® monotherapy: 86%

  • Patients receiving ZINFORO® concurrently with other antibiotics: 84%

Rationale for ZINFORO® use

In a recent retrospective study, the most common reason for using ZINFORO® was disease progression following prior therapies.3  
 

Real-world efficacy in patients with comorbidities and renal insufficiency4
Overall clinical success rates for evaluable patients with cSSTI by the category of renal function in the CAPTURE study* is represented below.
 

Rates of Clinical Success for Evaluable Acute Bacterial Skin and Skin Structure Infection Patients
 


Adapted from Maggoire C, et al. 2015.
 

Dosage adjustments were required in patients with moderate to severe renal impairment (CrCl ≥15 mL/min to ≤50 mL/min) and ESRD, including in patients undergoing haemodialysis.5

Real-world efficacy was demonstrated in obese patients with similar clinical success rates versus in patients with a normal BMI in the CAPTURE study.6,*,† 
 

Clinical Success Rates for Patients With Normal BMI and Obese or Morbidly Obese BMI​​​​​​​


Adapted from Evans JD, et al. 2014.​​​


ZINFORO® is suitable for patients across a range of BMIs and does not require dosing based on their weights.6
Above data are real-world and are, therefore, subject to potential confounding bias usually associated with observational research.





*CAPTURE was a retrospective cohort study relating to the current treatment practice in the United States. In CAPTURE, ‘clinical success’ was defined as clinical cure with no further need for antibiotic therapy or clinical improvement with switch to oral agents at the end of the ZINFORO® treatment. As CAPTURE is a retrospective chart review study, it has the limitations inherent to this study design.1
Normal BMI: 18.5 kg/m2 to ≤24.9 kg/m2; BMI in obese patients: ≥30 kg/m2; BMI in morbidly obese patients: ≥40 kg/m2.6


BMI, body mass index; CAPTURE, Clinical Assessment Program and TEFLARO® Utilization Registry; CrCl, creatinine clearance; cSSTI, complicated skin and soft tissue infection; ESRD, end-stage renal disease.



References:

Santos PD, Davis A, Jandourek A, Smith A, David Friedland H. Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience. J Chemother. 2013;25(suppl 6):341-346.
Stein GE, Wallace S, Jandourek A, et al. Ceftaroline fosamil for treatment of cSSTI due to Staphylococcus aureus with vancomycin MICs of 1.5 to 2 mg/L: CAPTURE Study Experience. Poster presented in ESCMID. Accessed April 26 2022. https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=16017.Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58(suppl 5):2541-2546.Maggiore C, Pasquale T, Cole P, Friedland HD. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency. Expert Rev Clin Pharmacol. 2015;8(suppl 1):141-153.
Zinforo. Local product document. Pfizer; 2021. Version LPDZIN072021.Evans JD, Udeani G, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients. Postgrad Med. 2014;126(suppl 5):128-134.


​​​​​Please click the Prescribing Information link to view the safety and adverse events information of ZINFORO®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
​​​​​​​
PP-ZFO-IND-0417 June 2022

Clinical & scientific data
About

Fifth-generation cephalosporin with broad coverage

Learn more

Dosing

Simple dosing with a flexible infusion time

Learn moreLoading

Safety

Safety profile consistent with other cephalosporins

Review safety profile

Clinical & Scientific Data

​​​​ZINFORO® in the treatment of CAP and cSSTI​​​​​​

Learn more


PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-ZFO-IND-0417

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 14 July 2022
Yes No
You are now leaving PfizerPro website

​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
​PP-UNP-IND-0012 14 July 2022